Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kiadis Crushed By EMA Rejection Of T-Cell Therapy

Launch Hopes For ATIR101 Pushed Back A Few Years

Executive Summary

The Dutch company's dataset on its stem cell transplant adjunct ATIR101 is not enough to satisfy European regulators as the standard of care in post-transplant patients has changed since the original filing.

You may also be interested in...



Sanofi Bids €308m To Buy Kiadis

Arthur Lahr, CEO of the Dutch biotech, said the offer is testimony to the uniqueness of the firm's natural killer (NK) cell platform "and the rapid success of Kiadis’s transformation."

Kiadis And Sanofi Sign Natural Killer Cell Therapy Pact

Sanofi is paying €17.5m upfront to combine a preclinical NK cell product with its anti-CD38 antibody Sarclisa and develop a multiple myeloma drug that potentially may prove more effective than J&J's Darzalex, Kiadis's CEO tells Scrip.

Finance Watch: Big Money For Big Goals Met By Reata, CRISPR, Karuna

Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC126048

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel